I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease
Identifieur interne : 004434 ( Main/Curation ); précédent : 004433; suivant : 004435I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease
Auteurs : C. Gargalidis-Moudanos [France] ; N. Pizzinat ; F. Javoy-Agid ; A. Remaury ; A. PariniSource :
- Neurochemistry international [ 0197-0186 ] ; 1997.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
I2-imidazoline binding site (I2BS) has been identified with a regulatory site located on a subpopulation of monoamine oxidase (MAO)-A and -B. Previous studies showed a modification of MAO and I2BS in the elderly and in neurodegenerative processes such as Alzheimer's disease. In the present study. we studied the potential modification of I2 binding sites and monoamine oxidases in Parkinson's disease. Putamen and cerebral cortex were collected from 17 normal subjects (79±12 yr) and 16 patients (76 ± 9 yr) affected by Parkinson's disease. In mitochondrial preparations, radioligand binding studies with [3H]idazoxan showed that putamen and frontal cortex express equivalent amount of I2BS. The density and affinity of I2BS were similar in normal subjects (putamen : Bmax = 207 ± 58 fmol/mg of protein, Kd = 10.1 ± 3.4 nM; cerebral cortex: Bmax = 193 ± 54 fmol/mg of protein. Kd=12.8±6.8 nM) and Parkinson's disease patients (putamen: Bmax = 193 ± 60 fmol/mg of proteins Kd = 9.8 ± 4.6 nM: cerebral cortex: Bmax = 199 ± 49 fmol/mg of protein, Kd = 15.9 ± 8.1 nM). The activity of total monoamine oxidase and monoamine oxidase B, measured by [14C]tyramine and ['4C]phenylethylamine oxidations respectively, were higher in putamen than in cerebral cortex. No differences have been detected in the enzyme activity between normal and pathological subjects. These data suggest that, although MAO and I2BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001764
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001882
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001573
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004C75
Links to Exploration step
Pascal:97-0163497Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">I<sub>2</sub>-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</title><author><name sortKey="Gargalidis Moudanos, C" sort="Gargalidis Moudanos, C" uniqKey="Gargalidis Moudanos C" first="C." last="Gargalidis-Moudanos">C. Gargalidis-Moudanos</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U388, Institut Louis Bugnard, CHU Rangueil</s1><s2>31054, Toulouse</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM U289, CHU Pitié-Salpetrière, 47 Boulevard de l'hôpital</s1><s2>75013, Paris</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pizzinat, N" sort="Pizzinat, N" uniqKey="Pizzinat N" first="N." last="Pizzinat">N. Pizzinat</name></author><author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name></author><author><name sortKey="Remaury, A" sort="Remaury, A" uniqKey="Remaury A" first="A." last="Remaury">A. Remaury</name></author><author><name sortKey="Parini, A" sort="Parini, A" uniqKey="Parini A" first="A." last="Parini">A. Parini</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">97-0163497</idno><date when="1997">1997</date><idno type="stanalyst">PASCAL 97-0163497 INIST</idno><idno type="RBID">Pascal:97-0163497</idno><idno type="wicri:Area/PascalFrancis/Corpus">001764</idno><idno type="wicri:Area/PascalFrancis/Curation">001882</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001573</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001573</idno><idno type="wicri:Area/Main/Merge">004C75</idno><idno type="wicri:Area/Main/Curation">004434</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">I<sub>2</sub>-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</title><author><name sortKey="Gargalidis Moudanos, C" sort="Gargalidis Moudanos, C" uniqKey="Gargalidis Moudanos C" first="C." last="Gargalidis-Moudanos">C. Gargalidis-Moudanos</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U388, Institut Louis Bugnard, CHU Rangueil</s1><s2>31054, Toulouse</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM U289, CHU Pitié-Salpetrière, 47 Boulevard de l'hôpital</s1><s2>75013, Paris</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pizzinat, N" sort="Pizzinat, N" uniqKey="Pizzinat N" first="N." last="Pizzinat">N. Pizzinat</name></author><author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name></author><author><name sortKey="Remaury, A" sort="Remaury, A" uniqKey="Remaury A" first="A." last="Remaury">A. Remaury</name></author><author><name sortKey="Parini, A" sort="Parini, A" uniqKey="Parini A" first="A." last="Parini">A. Parini</name></author></analytic><series><title level="j" type="main">Neurochemistry international</title><title level="j" type="abbreviated">Neurochem. int.</title><idno type="ISSN">0197-0186</idno><imprint><date when="1997">1997</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neurochemistry international</title><title level="j" type="abbreviated">Neurochem. int.</title><idno type="ISSN">0197-0186</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amine oxidase (flavin-containing)</term><term>Binding site</term><term>Brain (vertebrata)</term><term>Cerebral cortex</term><term>Enzymatic activity</term><term>Human</term><term>Imidazoline I2 receptor</term><term>Imidazoline receptor</term><term>Parkinson disease</term><term>Putamen</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Encéphale</term><term>Récepteur imidazoline</term><term>Site fixation</term><term>Amine oxidase (flavin-containing)</term><term>Activité enzymatique</term><term>Putamen</term><term>Cortex cérébral</term><term>Parkinson maladie</term><term>Homme</term><term>Récepteur imidazoline I2</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">I<sub>2</sub>-imidazoline binding site (I<sub>2</sub>BS) has been identified with a regulatory site located on a subpopulation of monoamine oxidase (MAO)-A and -B. Previous studies showed a modification of MAO and I<sub>2</sub>BS in the elderly and in neurodegenerative processes such as Alzheimer's disease. In the present study. we studied the potential modification of I<sub>2</sub> binding sites and monoamine oxidases in Parkinson's disease. Putamen and cerebral cortex were collected from 17 normal subjects (79±12 yr) and 16 patients (76 ± 9 yr) affected by Parkinson's disease. In mitochondrial preparations, radioligand binding studies with [<sup>3</sup>H]idazoxan showed that putamen and frontal cortex express equivalent amount of I<sub>2</sub>BS. The density and affinity of I<sub>2</sub>BS were similar in normal subjects (putamen : B<sub>max</sub> = 207 ± 58 fmol/mg of protein, K<sub>d</sub> = 10.1 ± 3.4 nM; cerebral cortex: B<sub>max</sub> = 193 ± 54 fmol/mg of protein. K<sub>d</sub>=12.8±6.8 nM) and Parkinson's disease patients (putamen: B<sub>max</sub> = 193 ± 60 fmol/mg of proteins K<sub>d</sub> = 9.8 ± 4.6 nM: cerebral cortex: B<sub>max</sub> = 199 ± 49 fmol/mg of protein, K<sub>d</sub> = 15.9 ± 8.1 nM). The activity of total monoamine oxidase and monoamine oxidase B, measured by [<sup>14</sup>C]tyramine and ['4C]phenylethylamine oxidations respectively, were higher in putamen than in cerebral cortex. No differences have been detected in the enzyme activity between normal and pathological subjects. These data suggest that, although MAO and I<sub>2</sub>BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004434 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004434 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Curation
|type= RBID
|clé= Pascal:97-0163497
|texte= I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |